Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fabiola Reginato"'
Autor:
Rafael Linden, Renata Leite, Pierre Wallemacq, Laura Fogliatto, Natalia Vieira, Marcelo Capra, Fabiola Reginato, Vanessa Suñé Mattevi, Arnaud Capron, Marina Venzon Antunes, Sandrine Comparsi Wagner
Publikováno v:
Clinica Chimica Acta. 453:42-47
Imatinib (IM) is a first choice drug for treatment of chronic myeloid leukemia (CML), with a widely accepted concentration threshold of 1000ng/ml being used as a target for therapeutic drug monitoring. Once adherence to the pharmacotherapeutic regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bf72d0f65c77965d8375af4dfec779
https://doi.org/10.1016/j.cca.2015.11.032
https://doi.org/10.1016/j.cca.2015.11.032
Autor:
Fabiola Reginato, Sandrine Comparsi Wagner, Rafael Linden, Natalia Vieira, Vanessa Suñé Mattevi, Suziane Raymundo, Marina Venzon Antunes, Renata Leite, Laura Fogliatto, Marcelo Capra
Publikováno v:
Bioanalysis. 7(16)
Background: Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml-1. DBS can increase access to IM therapeutic drug monitoring. Results: IM was measured in the range 50–4000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b06682deeac86358a36e3ed26a56cd
https://pubmed.ncbi.nlm.nih.gov/26327189
https://pubmed.ncbi.nlm.nih.gov/26327189
Autor:
Natalia Vieira, Fabiola Reginato, Vanessa Suñé Mattevi, Marcelo Capra, Pierre Wallemacq, Marina Venzon Antunes, Laura Fogliatto, Sandrine Comparsi Wagner, Renata Leite, Marília Remuzzi Zandoná, Tito Vanelli Costa, Rafael Linden, Arnaud Capron
Publikováno v:
Blood. 128:5458-5458
The treatment of chronic myeloid leukemia (CML) was revolutionized by the introduction of imatinib mesylate (IM). However, approximately 20% of patients are non-responsive and interpatient variability in response to IM is still a phenomenon lacking e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c03300a7a22fa2fd8fd9e730091c4c9
https://doi.org/10.1182/blood.v128.22.5458.5458
https://doi.org/10.1182/blood.v128.22.5458.5458